Your filter selection has no results
APEX
Phase 3b
Evaluate the efficacy and safety of
guselkumab in improving the
signs and symptoms and inhibiting radiographic progression in
participants with active psoriatic arthritis
STAR
Phase 4
Evaluate the efficacy and safety of
guselkumab in participants with
active psoriatic arthritis axial disease
SOLSTICE
Phase 3b
Evaluate the efficacy and safety of
guselkumab treatment in
participants with active psoriatic arthritis and inadequate response
and/or intolerance to a prior anti-tumor necrosis factor
AFFINITY
Phase 2a
Evaluate the efficacy and safety of
guselkumab plus golimumab
combination treatment in participants with active psoriatic
arthritis
and inadequate response to ≤2 prior
anti-tumor necrosis factor
therapies compared with guselkumab monotherapy
PSUMMIT-JR
Phase 3
Evaluate the pharmacokinetics and efficacy of
ustekinumab and guselkumab in juvenile
psoriatic arthritis
UNITED
Phase 3
Collect long-term safety data of subcutaneous
ustekinumab in pediatric participants with Crohn’s
disease, ulcerative colitis, or psoriatic arthritis
PAMPA
Phase 4
Collaborative study to evaluate whether
intervention
with guselkumab will prevent the progression of
psoriasis to psoriatic arthritis by diminishing
musculoskeletal power-doppler ultrasound findings
and significantly reduce or prevent the emergence
of synovio-enthesial phenotype
SPIREA
Phase 2
Evaluate the efficacy and safety of
nipocalimab
versus placebo in participants with active idiopathic
inflammatory myopathies
JASMINE
Phase 2
Evaluate the efficacy and safety of
nipocalimab
versus placebo in participants with active systemic
lupus erythematosus
THEIA
Phase 2
Evaluate the efficacy and safety of
guselkumab
compared with placebo, in combination with a 26-week
glucocorticoid taper regimen, in adult participants with
new-onset or relapsing giant cell arteritis
U-POPS
Phase 1
Evaluate the pharmacokinetics of ustekinumab
in
juvenile psoriatic arthritis and psoriasis
EVOLUTION
Phase 3
Determine whether switching to a selective interleukin-23 inhibitor (guselkumab) is more effective than switching to a second tumor necrosis factor inhibitor (golimumab) in adult participants with psoriatic arthritis who have an inadequate response to a tumor necrosis factor inhibitor
OTIS
Observational
Monitor planned and unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic effect of these medications and to follow live born infants for one year after birth
NCT03218488
Observational
Evaluate the
long-term safety of ustekinumab
in the treatment of pediatric participants aged 6 years and older
with moderate to severe plaque psoriasis
RESTORE-AD
Phase 2a
Evaluate the efficacy, safety, and tolerability of JNJ-67484703 in adult participants with moderate to severe atopic dermatitis
ASTRO
Phase 3
Evaluate the efficacy, including clinical
remission, of guselkumab
subcutaneous induction compared with placebo in adult
participants with moderately to severely active ulcerative colitis
FUZION CD
Phase 3
Evaluate efficacy of guselkumab in
fistulizing, perianal Crohn’s
disease and assess the overall safety of guselkumab
DUET-UC
Phase 2b
Evaluate efficacy and safety of
JNJ-78934804
compared with guselkumab and golimumab in adult
participants with moderately to severely active
ulcerative colitis
DUET-CD
Phase 2b
Evaluate the efficacy of JNJ-78934804
compared
with guselkumab and golimumab in adult patients
with moderately to severely active Crohn’s disease
UNIFI JR
Phase 3
Evaluate the efficacy, safety, and
pharmacokinetics
of ustekinumab in pediatric participants with
moderately to severely active ulcerative colitis
UNITI JR
Phase 3
Evaluate the efficacy, safety, and
pharmacokinetics
of ustekinumab in pediatric participants with
moderately to severely active Crohn’s disease
ENERGY
Phase 2/3
Evaluate the efficacy and safety of
nipocalimab compared with
placebo for the treatment of adult participants with warm
autoimmune hemolytic anemia
VIBRANCE MG
Phase 2/3
Evaluate the pharmacokinetics, pharmacodynamics, safety, and activity of nipocalimab in pediatric participants with generalized myasthenia gravis
VIVACITY MG3
Phase 3
Evaluate the efficacy and safety of nipocalimab compared to placebo in adult participants with generalized myasthenia gravis
ARISE
Phase 2/3
Evaluate the safety and efficacy of nipocalimab versus placebo in delaying relapse in adult participants with chronic inflammatory demyelinating polyneuropathy
United States
Outside of the United States
